If your child is still experiencing symptoms of moderately to severely active pediatric Crohn's disease (PCD), including flares more than 2 times a year, REMICADE® may be able to help keep his or her symptoms under control.
REMICADE® can reduce signs and symptoms and induce and maintain remission in children (ages 6–17) with moderately to severely active Crohn's disease who haven't responded well to other therapies.
Other ways your child may benefit from REMICADE®
- Approximately 88% of children (nearly 9 out of 10) experienced symptom improvement as soon as 10 weeks after starting treatment with REMICADE®
- Long-term periods of no symptoms or very few symptoms: In a year-long study of children with moderately to severely active PCD who began treatment with REMICADE®, many children experienced rapid symptom improvement (response) and long-term periods of no or very few symptoms (remission)
- Elimination of steroid use: REMICADE® may eliminate the need for steroids. Stopping steroid use may allow your child to avoid the potential serious side effects of steroids. Remember, only your child's doctor can decide if reducing or stopping steroids is appropriate. Like other medicines that affect your child's immune system, REMICADE® can also cause serious side effects
- Infrequent dosing: Dosing with REMICADE® is customized according to your child's weight. REMICADE® is given as a 2-hour IV infusion by a healthcare professional. Your child will need REMICADE® only once every 8 weeks after the 3 starter doses. That could be as few as 6 times a year
- Extensive experience: REMICADE® has been used to treat more than 1.3 million people worldwide who have conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults, PCD, ulcerative colitis, and ankylosing spondylitis
REMICADE® is not for everyone
SELECTED IMPORTANT SAFETY INFORMATION
REMICADE® can lower your child's ability to fight infections. Serious and sometimes fatal events can occur. There have been reports of serious infections including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that have spread throughout the body. Lymphoma, including a fatal kind called hepatosplenic T-cell lymphoma, and other cancers have been reported in children and adults taking REMICADE®. Some people with heart failure should not take REMICADE®. Other serious side effects reported include skin cancer, hepatitis B, liver injury, blood problems, allergic reactions, nervous system problems, or lupus-like syndrome. To learn more about these and other risks, please read the Important Safety Information and the Medication Guide , and talk with your doctor.